Skip to main content

Featured Post

Russia Holds Key Rate at 21% Amid Surging Inflation

The Bank of Russia unexpectedly maintained its key interest rate at a record-high  21% , defying analysts’ expectations of another significant hike as inflation remains stubbornly elevated. The decision marks a shift toward a more measured approach in balancing economic growth and price stability. Key Details Inflation Concerns: Annual inflation climbed to  8.9%  in November, well above the central bank’s  4% target , with inflation expectations reaching  13.9%  in December. Policy Rationale: The central bank cited the significant tightening of monetary conditions after October’s  200-basis point hike  as sufficient to resume disinflationary processes. Governor Elvira Nabiullina emphasized avoiding both economic overheating and severe slowdowns. Economic Overheating: Elevated government spending on the war in Ukraine and social programs, coupled with labor shortages and rising wages, have fueled strong domestic demand, exacerbating price pressures...
Post a Comment

GSK Acquires Lupus Drug from Chinese Biotech Chimagen in Deal Worth Up to US$850 Million

GSK plc has announced the acquisition of an experimental lupus drug from Chinese biotech company Chimagen Biosciences in a deal worth up to US$850 million (RM3.7 billion). This agreement enhances GSK's immunology pipeline, adding to its existing lupus treatment portfolio.

As part of the deal, GSK will pay US$300 million upfront, with Chimagen eligible for US$550 million in success-based milestone payments. While the drug is currently in early clinical trials for leukemia and lymphoma, GSK plans to begin clinical trials for lupus in 2025.

The British drugmaker already markets Benlysta, a blockbuster treatment for systemic lupus erythematosus and lupus nephritis, and is optimistic about the potential of the acquired drug to further address these autoimmune diseases.

Pharmaceutical companies are increasingly turning to China for innovative medicines. GSK recently secured a multi-billion-dollar deal for its shingles vaccine in China and signed a licensing agreement with Hansoh Pharma for an antibody-drug conjugate.

This latest move underscores GSK's strategic focus on expanding its offerings in immunology and autoimmune disease treatments.

Labels:

Comments

Post a Comment

Popular posts from this blog

特朗普考虑保罗·阿特金斯接任SEC主席，或推动加密货币监管转型

据彭博社报道，美国候任总统唐纳德·特朗普正在考虑由 保罗·阿特金斯 （Paul Atkins）接替即将卸任的证券交易委员会（SEC）主席 加里·根斯勒 （Gary Gensler）。阿特金斯以其支持数字资产的立场闻名，这一任命可能为SEC的加密货币监管政策带来重大转变。 事件概况 阿特金斯的背景 ： 阿特金斯曾在乔治·W·布什政府期间担任SEC专员。他一直推动制定明确且平衡的加密货币法规，力求为金融科技创新提供支持。 行业经验 ： 离开SEC后，阿特金斯领导了 Patomak Global Partners ，一家为主要金融公司提供咨询的机构。他主张简化监管流程以鼓励创新，同时确保市场完整性。 其他候选人 ： 马克·乌耶达 （Mark Uyeda）：现任SEC专员 希斯·塔伯特 （Heath Tarbert）：前商品期货交易委员会（CFTC）主席 罗伯特·斯特宾斯 （Robert Stebbins）：Willkie Farr & Gallagher LLP合伙人 特朗普的亲加密货币立场 特朗普承诺终结根斯勒领导下的SEC“反加密货币运动”。根斯勒的任期因FTX崩盘等丑闻后的强力执法而备受争议，被批评为给行业带来了不确定性。 阿特金斯的潜在任命与特朗普的目标一致，即在保障市场完整性的同时，通过更加友好的监管政策推动数字资产的发展。 接下来会发生什么？ SEC主席的任命预计将在未来几天内敲定。如果阿特金斯接任，这将表明SEC将采取更注重创新的监管方式，为加密货币行业带来更大的确定性和发展空间。
Post a Comment
Read more

INTC Share Watch and News

Stock Info Market Monitor Company Profile Intel Corporation designs, manufactures, and sells integrated circuits for computing and communications industries worldwide. It offers microprocessor products used in notebooks, netbooks, desktops, servers, workstations, storage products, embedded applications, communications products, consumer electronics devices, and handhelds. The company also offers system on chip products that integrate its core processing functionalities with other system components, such as graphics, audio, and video, onto a single chip. It also provides chipset products that send data between the microprocessor and input, display, and storage devices, such as keyboard, mouse, monitor, hard drive, and CD or DVD drives; motherboards that has connectors for attaching devices to the bus, and products designed for desktop, server, and workstation platforms; and wired and wireless connectivity products, including network adapters and embedded wireless cards used to translat...
1 comment
Read more

Capital A 股价下跌，因外汇驱动的第三季度业绩低于预期

Capital A Bhd 在周五早盘交易中股价下跌7%，至1.01令吉，市值降至46亿令吉。这是由于其2024财年第三季度业绩未达到大多数分析师预期，尽管受益于外汇收益提振。 2024财年第三季度亮点： 核心税后及少数股东权益后亏损 (Latmi)：  1.434亿令吉，令2024财年前9个月的税后亏损达到1.195亿令吉。 业绩未达  香港联昌投资银行（HLIB）预计的7.549亿令吉的税后净利（Patmi），但与市场普遍预测的4.59亿令吉税后净利一致。 剔除例外项目 (EIs)：  共计12亿令吉，主要由于15亿令吉的外汇收益，但被递延税务损失部分抵销。 环比表现： 核心Latmi从上一季度的5,760万令吉恶化至1.434亿令吉，主要受以下因素影响： 季节性收益率疲弱； 成本增加； ADE MRO（维修、保养及翻修）业务因6个新机库的启动成本造成亏损。 未来展望： 预计2024财年第四季度表现将有所改善，得益于： 更高的机队容量； 季节性需求和收益率的改善； 喷气燃料价格下降及美元贬值； 来自新ADE机库的运营贡献。 待决事项： 航空业务出售：  正等待法院批准出售给亚航长途（AirAsia X Bhd, KL:AAX），预计在2025财年第一季度完成。 PN17状态：  出售后仍维持，预计在2025财年上半年完成相关解决方案。 联昌投资银行（HLIB）建议： 维持“买入”评级，目标价为1.68令吉，估值基于航空业务为68亿令吉，非航空业务为21.5亿令吉。 尽管短期面临挑战，Capital A 的长期增长前景依然受到更强的季节性表现和战略举措的支持。
Post a Comment
Read more